:
Non-small cell lung cancer (NSCLC) is a leading cause of death in millions of cancer patients. Lack
of diagnosis at an early stage in addition to no specific guidelines for its treatment, and a higher rate of treatment-related toxicity further deteriorate the conditions. Current therapies encompass surgery, chemotherapy, radiation therapy, and immunotherapy according to the pattern and the stage of lung cancer. Among all, with a longlasting therapeutic action, reduced side-effects, and a higher rate of survival, therapeutic cancer vaccine is a
new, improved strategy for treating NSCLC. Immunoadjuvants are usually incorporated into the therapeutic
vaccines to shield the antigen against environmental and physiological harsh conditions in addition to boosting
the immune potential. Conventional immunoadjuvants are often associated with an inadequate cellular response, poor target specificity, and low antigen load. Recently, inhalable polymeric nano/micro immunoadjuvants have exhibited immense potential in the development of therapeutic vaccines for the treatment of NSCLC
with improved mucosal immunization. The development of polymeric micro/nano immunoadjuvants brought a
new era for vaccines with increased strength and efficiency. Therefore, in the present review, we explained the
potential application of micro/nano immunoadjuvants for augmenting the stability and efficacy of inhalable
vaccines in the treatment of NSCLC. In addition, the role of biodegradable, biocompatible, and non-toxic polymers has also been discussed with case studies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.